(Q42540132)

2 November 2017

1 reference

title

Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol (English)

1 reference

2 November 2017

0 references

G Feuerstein

1

1 reference

2 November 2017

T L Yue

series ordinal

2

1 reference

2 November 2017

X Ma

series ordinal

3

1 reference

2 November 2017

R R Ruffolo

series ordinal

4

1 reference

2 November 2017

publication date

1 July 1998

1 reference

Progress in Cardiovascular Diseases

2 November 2017

published in

1 reference

2 November 2017

volume

41

1 reference

2 November 2017

issue

1 Suppl 1

1 reference

2 November 2017

page(s)

17-24

1 reference

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitrone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Higher antioxidative capacity during a chronic stable heart hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Effect of chronic oral supplementation with alpha-tocopherol on myocardial stunning in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Elevated breath pentane in heart failure reduced by free radical scavenger.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Neurohormonal interactions and adaptations in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Scavenging of hypochlorous acid by carvedilol and ebselen in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Peroxyl radical scavenging activity of the antihypertensive drug carvedilol

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

A hydroxylated analog of the beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

To die or not to die: an overview of apoptosis and its role in disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Apoptosis and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

Apoptosis in myocytes in end-stage heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2898%2980027-3

7 January 2021

10.1016/S0033-0620(98)80027-3

Identifiers

DOI

1 reference

2 November 2017

1 reference